Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,835 followers
Take one (1) Maxicap twice a day, or as directed
But in the specific context of GLP-1 receptor agonist therapy, testosterone's role becomes particularly consequential, for a reason that goes to the heart of what these medications are actually trying to achieve
Vitamin C, hay cn c gi l axit ascorbic, l cht dinh dng m c th cn trong qu trnh hnh thnh mch mu, sn, c v collagen trong xng (2)
Generally, the answer is yes
Supporting healthy glutathione levels may help restore balance and improve sleep quality overall